MENU
Advertisement
Show Filters
Refine by Content Type
Refine by Year
Sort By:
Choose Sites to Search:
Cardiogenic Shock in STEMI
Current trends in management and the use of mechanical circulatory support devices.
By Manel Sabaté, MD, PhD; Teresa López-Sobrino, MD; and Salvatore Brugaletta, MD, PhD
Bare-Metal Stents for Primary PCI
Challenging the myths with evidence.
By Ander Regueiro, MD, and Manel Sabaté,, MD, PhD
iVascular’s ANGIODAPT RCT of Abbreviated DAPT After PCI Begins Enrollment
December 14, 2023—iVascular announced the initiation of its first randomized trial of an abbreviated dual antiplatelet therapy (DAPT) regimen after implantation of the company’s Angiolite drug-eluting stent to treat patients with coronary artery disease (CAD).
STEMI in Focus; Structural Imaging
By Salvatore Brugaletta, MD; Dee Dee Wang, MD; and Edwin Ho, MD
iVascular’s ANGIODAPT Trial Completes Enrollment
February 2, 2026—iVascular announced the completion of patient recruitment for the ANGIODAPT trial, which is evaluating ischemic and bleeding outcomes after implantation of the iVascular Angiolite drug-eluting stent and abbreviated dual antiplatelet therapy (DAPT).
Options in PCI and AMI
By Ted E. Feldman, MD, FESC, FACC, FSCAI
EXAMINATION Data Show Superiority of EES vs BMS at 5 Years
September 3, 2015—The European Society of Cardiology (ESC) announced that findings from the EXAMINATION trial demonstrated the superiority of a second-generation everolimus-eluting stent (EES) over a bare-metal stent (BMS) at 5 years.
